Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
Investment analysts at StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a report issued on Saturday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
斯托克新闻网的投资分析师在周六发布的一份报告中对Otmey(纳斯达克:One-Get Rating)的股票进行了报道。该经纪公司对这家生物制药公司的股票设定了“持有”评级。
Separately, Piper Sandler cut shares of Otonomy from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $3.00 to $0.50 in a research report on Thursday, October 13th.
另外,在10月13日星期四的一份研究报告中,派珀·桑德勒将Otmey的股票评级从增持下调至中性,并将该公司的目标价从3.00美元下调至0.50美元。
Otonomy Price Performance
高性价比
NASDAQ:OTIC opened at $0.08 on Friday. The firm has a 50-day moving average of $0.11 and a two-hundred day moving average of $0.71. The stock has a market cap of $4.40 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 1-year low of $0.06 and a 1-year high of $2.59.
纳斯达克:周五开盘报0.08美元。该公司的50日移动均线切入位在0.11美元,200日移动均线切入位在0.71美元。该股市值为440万美元,市盈率为-0.10,贝塔系数为1.31。Otomy的一年低点为0.06美元,一年高位为2.59美元。
Institutional Investors Weigh In On Otonomy
机构投资者在Otmey上发表看法
About Otonomy
关于Otomy
(Get Rating)
(获取评级)
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Otomy,Inc.是一家生物制药公司,在美国开发神经学疗法。该公司提供治疗耳鸣的N-甲基-D-天冬氨酸受体拮抗剂Gacycldine的持续暴露制剂OTO-313,以及治疗耳鸣的脑源性神经营养因子持续暴露制剂OTO-413,该制剂处于第二阶段临床试验,用于修复耳蜗突触和治疗噪音中语音听力困难。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免费获取StockNews.com关于OTMy的研究报告(OTIC)
- MarketBeat:回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温,标普500指数何去何从
- Cintas以经营杠杆击败通胀
- 你买下Palantir的决定可能只是个时间问题
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收《Otmey Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Otmey及相关公司评级的每日简要摘要。